May 14th 2024
During a Case-Based Roundtable® event, Jonathan L. Kaufman, MD, discussed which lines of therapy and at what doses would be appropriate to use selinexor in a patient with relapsed/refractory multiple myeloma in the second article of a 2-part series.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
FDA Grants Breakthrough Therapy Designation to Talquetamab for R/R Myeloma
June 29th 2022The FDA has granted breakthrough therapy designation to talquetamab for the treatment of previously-treated adult patients with relapsed or refractory multiple myeloma based on positive results from the phase 1/2 MonumenTAL-1 study.
Read More
Cilta-cel Shows Deep and Durable Responses for R/R Multiple Myeloma
June 22nd 2022Jesus G. Berdeja, MD, director of multiple myeloma research at Sarah Cannon Research Institute and hematology specialist at Tennessee Oncology, discusses the results of the CARTITUDE-1 trial for chimeric antigen receptor T-cell therapy with the newly-approved agent ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.
Watch
Transplant and Lenalidomide Maintenance Improves PFS in Newly Diagnosed Myeloma After RVd Treatment
June 5th 2022At the 2022 ASCO Annual Meeting findings from the phase, 3 DETERMINATION trial showed off the survival benefit when adding autologous stem cell transplant and lenalidomide maintenance after RVd treatment for patients with newly diagnosed multiple myeloma.
Read More
Daratumumab Added to RVd Achieved MRD Negativity, PFS Improvement in Newly Diagnosed Myeloma
June 5th 2022Among patients with newly diagnosed, transplant-eligible myeloma treated in a phase 2 study, induction and consolidation with daratumumab plus the RVd regimen outperformed RVd alone in terms of minimal residual disease and progression-free survival.
Read More
Where Does Inhibition of BCL-2 Family Proteins Fit into the Multiple Myeloma Treatment Landscape?
May 5th 2022Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. Drs. Shaji Kumar and Jonathan Kaufman discuss how BCL-2 inhibitors fit into the different treatment options for multiple myeloma.
Watch
Other Investigational Agents Targeting BCL-2 Family Proteins for Multiple Myeloma Treatment
May 5th 2022Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. An explanation of the focus on BCL-2 inhibitors versus the development of MCL-1 inhibitors for multiple myeloma treatment.
Watch
Part 2: Using Depth of Response and MRD as Goals for Multiple Myeloma
May 2nd 2022During a live virtual event, Douglas Sborov, MD, MS, discussed the most important goals for treatment and the use of minimal residual disease assessment for a patient with transplant-eligible multiple myeloma.
Read More